Larson Financial Group’s Seres Therapeutics MCRB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$17 Hold
5
– – ﹤0.01% 3823
2026
Q2
$39 Buy
+5
New +$38 ﹤0.01% 3693
2025
Q1
– Sell
-12
Closed -$195 – 3158
2024
Q4
$195 Hold
12
– – ﹤0.01% 2449
2024
Q3
$222 Hold
12
– – ﹤0.01% 2338
2024
Q2
$170 Hold
12
– – ﹤0.01% 2116
2024
Q1
$182 Hold
12
– – ﹤0.01% 1648
2023
Q4
$329 Hold
12
– – ﹤0.01% 1615
2023
Q3
$559 Hold
12
– – ﹤0.01% 1566
2023
Q2
$1.13K Hold
12
– – ﹤0.01% 1348
2023
Q1
$1.33K Hold
12
– – ﹤0.01% 1309
2022
Q4
$1.32K Hold
12
– – ﹤0.01% 1255
2022
Q3
$2K Buy
+12
New +$1.23K ﹤0.01% 1125

Other funds holding MCRB

Larson Financial Group's MCRB Position: Q3 2026 in Review

Larson Financial Group held its Seres Therapeutics (MCRB) position steady in Q3 2026 at 5 shares worth $17. The position accounts for ﹤0.01% of the portfolio, ranked #3823.

Larson Financial Group first reported a position in MCRB in Q3 2022 and has held it in 12 quarters since. The position peaked at $2K in Q3 2022. 40 funds tracked by Wall St. Rank hold MCRB as of Q3 2026.

  • Larson Financial Group held 5 shares of Seres Therapeutics worth $17 as of Q3 2026.
  • Larson Financial Group left its Seres Therapeutics share count unchanged in Q3 2026.
  • Seres Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q3 2026, its #3823 holding.
  • Larson Financial Group first reported a position in Seres Therapeutics in Q3 2022 and has held it in 12 quarters since.
  • Larson Financial Group's Seres Therapeutics position peaked at $2K in Q3 2022.
  • 40 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2026.

Based on Larson Financial Group's 13F filing for Q3 2026, filed 5 Nov 2026.